Ver­san­t's fourth obe­si­ty biotech starts with $65M and a GIP an­tag­o­nist

An­oth­er obe­si­ty biotech emerged on Tues­day morn­ing, this time tak­ing a dif­fer­ent ap­proach to the GIP an­tag­o­nism sto­ry than Am­gen and an­oth­er start­up called An­tag …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER